HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY. TIVICAY (dolutegravir) tablets for o

First Page		Document Content
Date: 2014-05-15 13:36:00 Protease inhibitors Fixed dose combination Gilead Sciences Bristol-Myers Squibb Darunavir Antiretroviral drug Emtricitabine/tenofovir/efavirenz Tenofovir/emtricitabine Raltegravir Chemistry Organic chemistry Organofluorides		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY. TIVICAY (dolutegravir) tablets for o Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 919,42 KB Share Document on Facebook

	Switching between raltegravir resistance pathways analyzed by deep sequencing Rithun Mukherjeea, Shane T. Jensenb, Frances Malea, Kyle Bittingera, Richard L. Hodinkac,d, Michael D. Millere and Frederic D. Bushmana Object DocID: 1rImN - View Document
	12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box DocID: 1qIwe - View Document
	Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (avrilANRS 160 RalFE Evaluation des propriétés pharmacocinétiques et de la tolérance du raltégravir pendant l DocID: 1lV9R - View Document
	ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL DocID: 1fNy0 - View Document
	Merck Sharp Dohme Haarlem raltegravir Isentress HIV aanbiedingsbrief rapporten ministerPOVOOPEN.DOC DocID: 1ey1D - View Document